Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients.

Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, Piselli P, Borghesi R, Mancino G, Brunetti E, Alimonti A.

Ann Oncol. 2010 Jul;21(7):1523-8. doi: 10.1093/annonc/mdp568. Epub 2009 Dec 23.

3.

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.

Cortesi E, Mancuso A, De Pasquale Ceratti A, Pizzardi N, D'Auria G, Accettura C, Beccaglia P, Bertelletti D, De Marinis F.

Oncologist. 2004;9(4):459-68.

4.
6.

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.

Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR, et al.

J Natl Cancer Inst. 1993 May 19;85(10):801-6.

PMID:
8487324
7.

An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Mustacchi G, Ceccherini R, Dellach C, Foladore S, Milani S, Leita M, Sisto M.

Ann Oncol. 2006 Nov;17(11):1705-8. Epub 2006 Sep 15.

8.

Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.

González-Barón M, Ordóñez A, Franquesa R, Constenla M, Montalar J, Gili F, Camps C, Sancho JF, Pérez-Cachot P.

Cancer. 2002 Dec 1;95(11):2408-13.

9.

A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.

Santini D, Vincenzi B, La Cesa A, Virzi V, Navajas F, Malafarina V, Dicuonzo G, Cassandro R, Esposito V, Montesarchio V, Groeger AM, Tonini G.

Anticancer Res. 2005 Jan-Feb;25(1B):669-74.

10.

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.

Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L, Soubeyran P; European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly.

Eur J Cancer. 2007 Jan;43(2):258-70. Epub 2006 Dec 19. Review.

PMID:
17182241
12.
13.

Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.

Oncologist. 2004;9(1):90-6. Erratum in: Oncologist. 2004;9(2):240.

14.

[Influence of erythropoietin on immunological system of patients with chronic renal failure].

Debska-Slizień A, Rutkowski B, Manitius J, Zdrojewski Z, Szołkiewicz M, Bułło B, Lizakowski S, Myśliwska J, Myśliwski A, Bryl E, Trzonkowski P, Bakowska A, Rachoń D.

Pol Merkur Lekarski. 2003 Oct;15(88):326-7; discussion 327-9. Polish.

PMID:
14974359
15.

Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.

Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A.

Clin Lab Haematol. 1997 Sep;19(3):197-201.

PMID:
9352145
16.

Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.

Varan A, Büyükpamukçu M, Kutluk T, Akyüz C.

Pediatrics. 1999 Feb;103(2):E16.

PMID:
9925862
17.

Assessment of the efficacy of two dosages and schedules of human recombinant erythropoietin in the prevention and correction of cisplatin-induced anemia in cancer patients.

Mantovani G, Ghiani M, Curreli L, Maccio A, Massa D, Succu G, Lai P, Massa E, Mudu MC, Astara G.

Oncol Rep. 1999 Mar-Apr;6(2):421-6.

PMID:
10023014
18.

Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.

Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y.

Haematologica. 1996 Sep-Oct;81(5):434-41.

19.

A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy.

Pawlicki M, Jassem J, Bösze P, Lotan C, Kurteva GP, Siddiqui M, Kosmidis PA, Rigatos GA, Kansu E, Durkovic P, Aziz Z, Al Idrissi H, Roth A, Cozma G.

Anticancer Drugs. 1997 Nov;8(10):949-57.

PMID:
9436638
20.

Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

Voravud N, Sriuranpong V, Suwanrusme H.

J Med Assoc Thai. 2007 Jun;90(6):1082-8.

PMID:
17624200
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk